Comparative Pharmacology
Head-to-head clinical analysis: DARICON versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARICON versus HICON.
DARICON vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Daricon (oxyphencyclimine) is a competitive antagonist of muscarinic acetylcholine receptors (M1-M5), inhibiting parasympathetic nerve impulses. It reduces gastrointestinal motility, gastric acid secretion, and smooth muscle spasm by blocking cholinergic activity at effector cells.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
5 mg orally three times daily. Maximum dose: 15 mg per day.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours; clinical context: allows twice-daily dosing
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Renal (70% unchanged, 30% as metabolites); biliary/fecal (10%)
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic
Anticholinergic